SCHEMBL7959847

SCHEMBL7959847

CC(C)(C)OC(=O)N1CCCC2(CC(=O)c3cc(-c4cccc(C#N)c4)ccc3O2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 7/20 0.46
HDAC4 P56524 7/20 0.46
HDAC1 Q13547 7/20 0.46
HDAC7 Q8WUI4 7/20 0.46
HDAC2 Q92769 7/20 0.46
HDAC10 Q969S8 7/20 0.46
HDAC11 Q96DB2 7/20 0.46
HDAC8 Q9BY41 7/20 0.46
HDAC6 Q9UBN7 7/20 0.46
HDAC9 Q9UKV0 7/20 0.46
HDAC5 Q9UQL6 7/20 0.46
USP30 Q70CQ3 1/20 0.42
GPR119 Q8TDV5 6/20 0.41
BACE1 P56817 1/20 0.40
PGR P06401 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7950811 0.91 KMT2A (0.49) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL12247499 0.85 HDAC3 (0.46) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1546891 0.81 HDAC3 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL12299455 0.81 PGR (0.44) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL309439 0.81 KMT2A (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3492047 0.81 KMT2A (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10258244 0.80 HDAC3 (0.49) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2375693 0.80 BACE1 (0.56) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7949753 0.78 PGR (0.44) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL309037 0.77 GPR119 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP HDAC3 1520/4885HDAC4 1303/4885HDAC1 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.